Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries.
OBJECTIVE
To determine the effect of the androgen supplementation of hormone replacement therapy (HRT) on the vascular reactivity of cerebral arteries.


METHODS
Open randomized study.


METHODS
Healthy volunteers in an academic research environment.


METHODS
Forty postmenopausal women who were treated with sequential HRT (transdermal E2 50 microg/d + medroxyprogesterone acetate 10 mg/d for 12 days every other month) for > or =1 year and < or =5 years.


METHODS
Testosterone undecanoate (40 mg/d, p.o.) was randomly administered to 20 patients during ongoing HRT; the other 20 served as controls. Doppler evaluations of the internal carotid and middle cerebral arteries were performed together with lipid levels assessments. A visual analogue scale (VAS) was used to evaluate various parameters relating to sexual life and well-being.


METHODS
Pulsatility index (PI) of the arteries, VAS assessment of psychophysical well-being.


RESULTS
The administration of testosterone undecanoate during HRT induced an increase in the PI of the middle cerebral artery and a reduction of high-density lipoprotein cholesterol. Sexual desire and satisfaction were greatly improved.


CONCLUSIONS
In postmenopausal women, androgen supplementation during HRT can partially counteract the beneficial effects of estrogens on cerebral vascular reactivity and lipid profiles, but sexual desire and satisfaction are greatly improved.
Penotti
M
M
Istituti Clinici di Perfezionamento, University of Milan, Italy.
Sironi
L
L
Cannata
L
L
Viganò
P
P
Casini
A
A
Gabrielli
L
L
Vignali
M
M
D000279:Administration, Cutaneous; D002536:Cerebral Arteries / Q000187:drug effects*; D008076:Cholesterol, HDL / Q000378:metabolism; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008875:Middle Aged; D011788:Quality of Life; D012725:Sexual Behavior / Q000187:drug effects; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D045165:Testosterone Congeners / Q000008:administration & dosage / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects
D008076:Cholesterol, HDL; D045165:Testosterone Congeners; D013739:Testosterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; C010792:testosterone undecanoate